Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA class II and response to interferon-beta in multiple sclerosis.

Acta neurologica Scandinavica - 1 Dec 2005

Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo J A, Alonso A, Romero F, Leyva L, Alonso A, Luque G, de Ramón E

Abstract excerpt

OBJECTIVE: To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon-beta (IFN-beta). METHODS: We analysed the HLA class II genotypes of 96 multiple sclerosis (MS) patients treated with IFN-beta. The patients were classified as responders or non-responders according to clinical criteria: one or more relapses or a sustained increase after 1 year treatment compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disability Evaluation
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens Class II

Share to Injections, Intramuscular

Share to Injections, Subcutaneous

Share to Interferon-beta

Share to Multiple Sclerosis

Share to Neurologic Examination

Source

Identifiers

PMID: 16281922
DOI: 10.1111/j.1600-0404.2005.00415.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA class II and response to interferon-beta in multiple sclerosis.PMID 16281922Read ↗

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.Semantic proximity Read ↗

HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple SclerosisSemantic proximity Read ↗

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.Semantic proximity Read ↗

HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients.Semantic proximity Read ↗

HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.Semantic proximity Read ↗

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.Semantic proximity Read ↗

Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis.Semantic proximity Read ↗

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study.Semantic proximity Read ↗

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read ↗

Genetic Variant HLA DRB1*0403 and Therapeutic Response to Diseases Modifying Therapies in Multiple Sclerosis: A Case‐Control StudySemantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.